<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682590</url>
  </required_header>
  <id_info>
    <org_study_id>Quenot IDEAL-ICU</org_study_id>
    <nct_id>NCT01682590</nct_id>
  </id_info>
  <brief_title>I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus Late in Intensive Care Unit)</brief_title>
  <official_title>Early Initiation of Dialysis at the Failure Stage Versus Deferred Dialysis in Intensive Care Unit Patients in Premature Phase of the Septic Shock Who Develop Acute Renal Insufficiency. Randomized, Controlled Superiority Trial. IDEAL-ICU (Initiation od Dialysis Early vs Late in Intensive Care Unit) Study Group.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute renal failure is one of the most feared complications of septic shock and occurs in
      51% of patients with these conditions. Mortality at 3 months ranges from 36% to 60%. To
      date, these exists no consensus regarding the optimal time to initiate hemodialysis.
      Retrospective and observational studies have suggested that early initiation of hemodialysis
      could help to improve prognosis in these patients. Therefore, we aim to investigate wether
      early initiation of hemodialysis (within 12 hours after a diagnosis of acute renal
      insufficiency at the &quot;failure&quot; stage according to the RIFLE Criteria), will reduce 90-day
      mortality as compared to deferred initiation of hemodialysis (48 to 60 hours after
      diagnosis), in intensive care unit (ICU) patients with septic shock who develop acute renal
      failure.

      Secondary objectives include: to compare the impact of the two hemodialysis strategies on
      28, 180 et 360 day mortality, duration of mechanical ventilation, duration of hemodialysis,
      duration of ICU stay and duration of overall hospital stay. In addition, quality of life at
      90 and 360 days will be evaluated using the EQ5D questionnaire. Tolerance of both strategies
      will be compared in terms of metabolic disorders, arrhythmias, pulmonary oedema by overload,
      hypotension, hemorrhagic complications, and dependence on dialysis at hospital discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate whether early initiation of hemodialysis (within 12 hours after a diagnosis of acute renal insufficiency at the &quot;failure&quot; stage according to the RIFLE Criteria), will reduce 90-day mortality as compared to deferred initiation of hemodialysis (48 to 60 hours after diagnosis), in intensive care unit (ICU) patients with septic shock who develop acute renal failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the tolerance and evaluation quality of life</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary objectives include: to compare the impact of the two hemodialysis strategies on 28, 180 and 360 day mortality, duration of mechanical ventilation, duration of hemodialysis, duration of ICU stay and duration of overall hospital stay. In addition, quality of life at 90 and 360 days will be evaluated using the EQ5D questionnaire. Tolerance of both strategies will be compared in terms of metabolic disorders, arrhythmias, pulmonary oedema by overload, hypotension, hemorrhagic complications, and dependence on dialysis at hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">824</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Renal Failure (as Defined by the &quot;Failure&quot; Stage of the RIFLE Classification)</condition>
  <arm_group>
    <arm_group_label>Early initiation of dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start of hemodialysis within a maximum of 12 hours after diagnosis of acute renal failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start of hemodialysis between 48 and 60 hours after diagnosis of acute renal failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemodialysis</intervention_name>
    <arm_group_label>Early initiation of dialysis</arm_group_label>
    <arm_group_label>Deferred hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults (males or females, age &gt;18 years) with septic shock who develop acute renal failure
        (as defined by the &quot;Failure&quot; stage of the RIFLE classification) will be eligible for
        inclusion.

        Septic shock is defined as severe sepsis with at least 2 to 4 &quot;SIRS&quot; criteria and
        persistent hypotension despite adequate vascular filling and/or need for intropic or
        vaso-active drugs.

        SIRS is defined as the simultaneous presence of at least 2 of the following criteria :

          -  Body temperature ≥ 38°C ou ≤ 36°C

          -  Heart rate ≥ 90 bpm

          -  Respiratory rate ≥ 20/mn or PaCO2 ≤ 32 mmHg

          -  Leucocytes ≥ 12,000/mm3 or ≤ 4,000/mm3 or &gt;10% immature forms.

        Acute renal insufficiency is defined as the &quot;failure&quot; stage of the RIFLE classification,
        i.e. the presence of at least one of the following criteria:

          -  Increased creatinine x 3 times the baseline value

          -  Oliguria &lt; 0.3 ml/kg/h for 12 hours

        All patients are required to provide informed consent after having been appropriately
        informed about the study. In case of temporary incapacity of the patient to sign, the
        consent form can be signed by a surrogate.

        Exclusion Criteria:

        Patients presenting any of the following criteria will not be eligible for inclusion in
        the study:

          1. Patients with chronic renal at dialysis.

          2. Patients presenting acute renal failure of type obstructive and patients already
             presenting emergency criteria for immediate hemodialysis at the time of randomization
             (i.e. hyperkalemia &gt;6.5 mmol/L or pH&lt;7.15 or pulmonary oedema by fluid overload)

          3. Patients already had hemodialysis before their arrival in the intensive care unit

          4. Pregnant women.

          5. Moribund patients whose life expectancy is less than 24 hours

          6. Patients unlikely to survive to 28 days because of uncontrollable comorbidities (e.g.
             cardiac, pulmonary or hepatic disease at the terminal stage, hepatorenal syndrome,
             uncontrolled cancer, severe post-anorexic encephalopathy…)

          7. Patients with advance directives indicating their wish not to be resuscitated.

          8. Patients under legal guardianship.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pierre QUENOT</last_name>
    <phone>3 80 29 36 85</phone>
    <phone_ext>33</phone_ext>
    <email>jean-pierre.quenot@chu-dijon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saber Davide BARBAR</last_name>
    <phone>4 66 68 33 20</phone>
    <phone_ext>33</phone_ext>
    <email>saber.barbar@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Belfort</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio BADIE</last_name>
      <phone>3 84 98 50 69</phone>
      <phone_ext>33</phone_ext>
      <email>mfeissel@chbm.fr</email>
    </contact>
    <investigator>
      <last_name>Julio BADIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CAPELLIER</last_name>
      <phone>3 81 66 82 59</phone>
      <phone_ext>33</phone_ext>
      <email>gilles.capellier@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles CAPELLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BLASCO</last_name>
      <phone>3 81 66 81 66</phone>
      <phone_ext>33</phone_ext>
      <email>gblasco@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles BLASCO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chalon-Sur-Saône</name>
      <address>
        <city>Chalon-Sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc DOISE</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc DOISE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Dieppe</name>
      <address>
        <city>Dieppe</city>
        <zip>76200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe RIGAUD</last_name>
      <phone>2 32 14 75 50</phone>
      <phone_ext>33</phone_ext>
      <email>jrigaud@ch-dieppe.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe RIGAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DIJON Général</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MILESI</last_name>
      <phone>3 80 29 53 78</phone>
      <phone_ext>33</phone_ext>
      <email>nadine.milesi@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine MILESI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT</last_name>
      <phone>3 80 29 36 85</phone>
      <phone_ext>33</phone_ext>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond-Poincaré GARCHES (AP-HP)</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djillali ANNANE</last_name>
      <phone>1 47 01 07 86</phone>
      <phone_ext>33</phone_ext>
      <email>djillali.annane@rpc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Djillali ANNANE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de LA ROCHE sur YON</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean REIGNIER</last_name>
      <email>jean.reignier@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Jean REIGNIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de l'institut Catholique de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry VAN DER LINDEN</last_name>
      <phone>3 20 22 50 26</phone>
      <phone_ext>33</phone_ext>
      <email>vanderlinden.thierry@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Thierry VAN DER LINDEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent ARGAUD</last_name>
      <phone>4 72 11 00 15</phone>
      <phone_ext>33</phone_ext>
      <email>laurent.argaud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent ARGAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Melun</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehran MONCHI</last_name>
      <phone>1 64 71 60 10</phone>
      <phone_ext>33</phone_ext>
      <email>m.monchi@free.fr</email>
    </contact>
    <investigator>
      <last_name>Mehran MONCHI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir JABER</last_name>
      <phone>4 67 33 72 71</phone>
      <phone_ext>33</phone_ext>
      <email>s-jaber@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Samir JABER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHG Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GUIOT</last_name>
      <phone>3 89 64 61 26</phone>
      <phone_ext>33</phone_ext>
      <email>guiotp@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe GUIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LEVY</last_name>
      <email>b.levy@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno LEVY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saber Davide BARBAR</last_name>
      <phone>3 80 29 36 85</phone>
      <phone_ext>33</phone_ext>
      <email>saber.barbar@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Saber Davide BARBAR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph (APHP)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît MISSET</last_name>
      <phone>1 44 12 34 15</phone>
      <phone_ext>33</phone_ext>
      <email>bmisset@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Benoît MISSET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien BOHE</last_name>
      <email>julien.bohe@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Julien BOHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël COUSSON</last_name>
      <phone>3 26 78 30 22</phone>
      <phone_ext>33</phone_ext>
      <email>jcousson@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Joël COUSSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre - CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent CASTELAIN</last_name>
      <phone>3 88 12 79 13</phone>
      <phone_ext>33</phone_ext>
      <email>vincent.castelain@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent CASTELAIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Nouvel hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI</last_name>
    </contact>
    <investigator>
      <last_name>Ferhat MEZIANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Metz</name>
      <address>
        <city>Thionville</city>
        <zip>57100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume LOUIS</last_name>
      <phone>6 47 93 74 69</phone>
      <phone_ext>33</phone_ext>
      <email>gus_louis@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume LOUIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Vesoul</name>
      <address>
        <city>Vesoul</city>
        <zip>70000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah VALETTE</last_name>
      <phone>3 84 96 67 82</phone>
      <phone_ext>33</phone_ext>
      <email>s.valette@chi70.fr</email>
    </contact>
    <investigator>
      <last_name>Sarah VALETTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 6, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock; acute renal failure; hemodialysis; mortality.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
